UK Medicinal Cannabis Producer Secures New Funding
In a significant move for the medicinal cannabis industry, Grow Group, a prominent producer licensed by the MHRA, has successfully secured multimillion-pound financing. This decision comes after the company opted against an outright sale, instead pursuing a strategic debt-for-equity swap and additional equity investment.
What Financing Options Did Grow Group Pursue?
Grow Group has announced a £2 million equity injection from existing shareholders, alongside a £10 million debt-for-equity swap and an extension of maturity dates. This robust refinancing package is pivotal for strengthening the company's operations within the competitive medicinal cannabis market.
Who Are the New Co-Chief Executives of Grow Group?
In terms of leadership, Clare Holliday and Pierre van Weperen are to take over as co-chief executives. They will take over from the company’s founder, Ben Langley, who will continue to serve as a director following the refinancing move. This leadership change is expected to guide the company toward further innovation and growth.
What Is Grow Group's Role in the Medicinal Cannabis Market?
Founded in 2017, Grow Group has rapidly emerged as one of the UK’s largest suppliers of quality prescribed cannabis medicines. With operations primarily based in the UK, the company also markets its products in Australia and Germany. The legalization of medical cannabis in the UK since 2018 has opened significant opportunities for firms like Grow Group, particularly as medicinal products are now prescribable for various conditions such as chronic pain, anxiety, and epilepsy.
How Is Grow Group Meeting Market Demand?
According to Clare Holliday, the company is committed to launching new products monthly, all manufactured in their state-of-the-art UK facility. This approach ensures prescribers and patients have access to high-quality, consistent cannabis products, alongside a diverse portfolio of cannabis flowers.
Analysis from Prohibition Partners underlines that the UK is Europes second-largest market for cannabis-based medicines. There are roughly 140,000 active medical users predicted this year. Grow Group's innovative strategies and expansion plans position it favorably within this growing market.
More From Soft Secrets:
UK to Ban THCA and HHC: What This Means for Cannabinoid Products
L
Liz Filmer
